Prof. Wolfram C. M. Dempke

University of Munich, Germany

Email: wdempke@googlemail.com

Qualifications

2019 DBA., University of Middlesex, UK

2015 Ph.D., Open University of Hamburg, Germany

2008 MD., University of Munich, Germany

2000 MD., University of Halle, Germany

Publications (Selected)

1. Liang W, Cai K, Chen C, Chen H, Chen Q, Fu J, Hu J, Jiang T, Jiao W, Li S,Liu D, Liu W, Liu Y, MA, H, Pan X, Qiao G, Tian H, Wei L, Zhang Y, Zhao S, Zhao X, Zhou C, Zhu Y, Rosell R, Provencio M, Massarelli E, Antonoff MB, Hida T, de Perrot M, Lin SH, Di Maio M, Rossi A, de Ruysscher D, Raimirez RA, Dempke WCM, He J: Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 6: 2696-2715 (2020)
2. Uciechowski P, Dempke WCM: Interleukin-6 (IL-6) – a masterplayer in the cytokine network. Oncology 98: 131-137 (2020)
3. Manz K, Fenchel K, Eilers A, Morgan J, Wittling K, Dempke W: Efficacy and safety of approved first-line tyrosine kinase inhibitor treatment in patients with metastatic renal cell carcinoma: a network meta-analysis based on phase II/III randomized clinical trials Adv Ther 37: 730-744 (2020)
4. Dempke WCM, Fenchel K, Dale SP: PD-L1 as a biomarker for NSCLC – are we barking up the wrong tree? Transl Lung Cancer Res 7 (Suppl 3): 275-279 (2018)
5. Dempke WCM, Fenchel K: Durvalumab for unresectable non-small cell lung cancer – a small step or a big leap? Transl Lung Cancer Res 7 (Suppl 2): 153-157 (2018)
6. Dempke WCM, Uciechowski P, Fenchel K, Chevassut T: Targeting SHP-1,2 and SHIP pathways – a novel strategy for cancer treatment? Oncology 95: 257-269 (2018)
7. Dempke WCM, Fenchel K: Treating EGFR-mutant NSCLC – is dacomitinib the winner? Transl Lung Cancer Res 6 (Suppl 1): 88-91 (2017)
8. Dempke WCM, Fenchel K, Uciechowski P, Chevassut T: Targeting developmental pathways – the Achilles heel of cancer treatment? Oncology 93: 213-223 (2017)
9. Dempke WCM, Fenchel K, Uciechowski P, Dale SP: Second and third generation drugs for immune-oncology – the more the better? Eur J Cancer 74: 55-72 (2017)
10. Dempke WCM, Fenchel K: Pembrolizumab as first-line therapy for NSCLC – a game changer? Transl Lung Cancer Res 5: 538-542 (2016)
11. Fenchel K, Dale SP, Dempke WCM: Improved overall survival following TKI treatment in NSCLC – are we making progress? Transl Lung Cancer Res 5: 373-376 (2016)
12. Fenchel K, Sellmann L, Dempke WCM: Overall survival in NSCLC – what is clinically meaningful? Trans Lung Cancer Res 5: 115-119 (2016)
13. Dempke WCM, Sellmann K, Fenchel K, Edvardsen K: Immunotherapies for NSCLC: Are we cutting the Gordian helix? Anticancer Res 35: 5745-5757 (2015)
14. Dempke WCM, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A: Brain metastases in NSCLC – are TKIs changing the treatment strategy? Anticancer Res 35: 5797-5806 (2015)
15. Sellmann L, Fenchel K, Dempke WCM: Improved overall survival following TKI treatment in advanced/metastatic NSCLC – The Holy Grail for cancer treatment? Transl Lung Cancer Res 4: 223-227 (2015)
16. Dempke WCM: Targeted therapy for NSCLC – a double-edged sword? Anticancer Res 35: 2503-2512 (2015)
17. Dempke S, Dempke W: Herausforderung Krebs. NOVA Heft 1: 6-9 (2014)
18. Dempke WCM: Gefitinib in non-small cell lung cancer – an old lesson new re-visited. Transl Lung Cancer Res 2: 435-438 (2013)
19. Faussner F, Dempke WCM: Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy. A meta-analysis. Anticancer Res 32: 2103-2109 (2012)
20. Dempke W, Heinemann V: Ras mutational status is a biomarker for resistance to EGF-R inhibitors in colorectal carcinomas. Anticancer Res 30: 4673-4678 (2010)
21. Dempke W, Zippel R: Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor. Anticancer Res 30: 4477-4484 (2010)
22. Eisenmann S, Voigt W, Mueller T, Dempke W: Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro. Anticancer Res 30: 4471-4476 (2010)
23. Dempke W, Zippel R: Src-Kinase-Inhibitoren in der Tumortherapie. Med Klinik 105: 711-715 (2010)
24. Dempke W, Suto T, Reck M: Targeted therapies in NSCLC. Lung Cancer 67: 257-274 (2010)
25. Dempke W, Heinemann V: Resistance to EGF-R (erbB1) and VEGF-R modulating agents. Eur J Cancer 45: 1117-1128 (2009)